Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Isolation and Characterization of Distinct Rotavirus A in Bat and Rodent Hosts. | J Virol | 2023 | 36633410 | PubTator, text mining | PubMed |
| Innate immune evasion strategies of SARS-CoV-2. | Nat Rev Microbiol | 2023 | 36631691 | PubTator, text mining | PubMed |
| A computational study on the molecular mechanisms of panduratin A as a potential inhibitor on SARS-CoV-2 protein targets. | Heliyon | 2023 | 36628324 | PubTator, text mining | PubMed |
| The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. | Virol J | 2023 | 36627683 | PubTator, text mining | PubMed |
| A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2. | Sci Rep | 2023 | 36627366 | PubTator, text mining | PubMed |
| Inhibition of SARS-CoV2 viral infection with natural antiviral plants constituents: An in-silico approach. | J King Saud Univ Sci | 2023 | 36619666 | PubTator, text mining | PubMed |
| A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? | Inflammopharmacology | 2023 | 36609716 | PubTator, text mining | PubMed |
| Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics. | Int J Antimicrob Agents | 2023 | 36603694 | PubTator, text mining | PubMed |
| Human Endogenous Retrovirus (HERV) Transcriptome Is Dynamically Modulated during SARS-CoV-2 Infection and Allows Discrimination of COVID-19 Clinical Stages. | Microbiol Spectr | 2023 | 36602345 | PubTator, text mining | PubMed |
| Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations. | Sci Rep | 2023 | 36599900 | PubTator, text mining | PubMed |
| A G3P[9] rotavirus strain with an unusual genome constellation in a diarrheic cat in Thailand. | Arch Virol | 2023 | 36593426 | PubTator, text mining | PubMed |
| Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease. | Bioorg Med Chem Lett | 2023 | 36587873 | PubTator, text mining | PubMed |
SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. | Comput Biol Med | 2023 | 36586228 | PubTator, text mining | PubMed |
| SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. | Acc Chem Res | 2023 | 36580641 | PubTator, text mining | PubMed |
| Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection. | Biochim Biophys Acta Mol Basis Dis | 2023 | 36577469 | PubTator, text mining | PubMed |
| Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies. | Saudi Pharm J | 2023 | 36540698 | PubTator, text mining | PubMed |
| A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2. | 3 Biotech | 2023 | 36532857 | PubTator, text mining | PubMed |
| Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. | Vaccine | 2023 | 36528447 | PubTator, text mining | PubMed |
| SARS-CoV-2 infection of companion animals in Egypt and its risk of spillover. | Vet Med Sci | 2023 | 36516308 | PubTator, text mining | PubMed |
| Phosphorylation of enteroviral 2Apro at Ser/Thr125 benefits its proteolytic activity and viral pathogenesis. | J Med Virol | 2023 | 36511115 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=30